Skip to main content
Atrás
BIO logo

Bio-Rad Laboratories, Inc.

Calidad de datos: 100%
BIO
NYSE Healthcare Medical - Devices
$265.00
▲ $0.51 (0.19%)
Cap. Mercado: 7.15B
Rango del Día
$264.01 $268.70
Rango de 52 Semanas
$211.43 $343.12
Volumen
299,834
Promedio 50D / 200D
$287.77 / $286.16
Cierre Anterior
$264.49

Historial de Precios

Tendencias Financieras

Comparación con Pares

vs mediana del sector Healthcare (626 pares)

Métrica Acción Mediana del Sector
P/E 9.4 0.4
P/B 1.0 2.9
ROE % 10.8 3.8
Net Margin % 29.4 3.9
Rev Growth 5Y % -3.0 10.0
D/E 0.2 0.2

Precio Objetivo de Analistas

Hold
$327.50 +23.6%
Low: $320.00 High: $335.00
P/E Futuro
25.9
EPS Futuro
$10.25
Crecimiento EPS (est.)
+0.0%
Ingresos Est.
2.6 B

Estimaciones de Ganancias

Período EPS Est. Ingresos Est. Analistas
FY2029 $14.30
$14.03 – $14.57
 2.9 B 1
FY2028 $12.53
$12.29 – $12.76
 2.8 B 1
FY2027 $11.50
$11.28 – $11.71
 2.7 B 2

Puntos Clave

Revenue declined -3.04% annually over 5 years
ROE of 10.84% — decent returns on equity
Net margin of 29.42% shows strong profitability
Debt/Equity of 0.21 — conservative balance sheet
Generating 374.60M in free cash flow
P/E of 9.41 — trading at a low valuation

Crecimiento

Revenue Growth (5Y)
-3.04%
Revenue (1Y)0.65%
Earnings (1Y)N/A
FCF Growth (3Y)31.01%

Calidad

Return on Equity
10.84%
ROIC2.26%
Net Margin29.42%
Op. Margin10.47%

Seguridad

Debt / Equity
0.21
Current Ratio5.62
Interest Coverage5.52

Valoración

P/E Ratio
9.41
P/B Ratio0.96
EV/EBITDA30.14
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 0.65% Revenue Growth (3Y) -1.66%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -3.04% Earnings Growth (5Y) -34.99%
Profitability
Revenue (TTM) 2.58B Net Income (TTM) 759.90M
ROE 10.84% ROA 7.18%
Gross Margin 52.01% Operating Margin 10.47%
Net Margin 29.42% Free Cash Flow (TTM) 374.60M
ROIC 2.26% FCF Growth (3Y) 31.01%
Safety
Debt / Equity 0.21 Current Ratio 5.62
Interest Coverage 5.52 Dividend Yield 0.00%
Valuation
P/E Ratio 9.41 P/B Ratio 0.96
P/S Ratio 2.77 PEG Ratio -0.08
EV/EBITDA 30.14 Dividend Yield 0.00%
Market Cap 7.15B Enterprise Value 8.15B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 2.58B 2.57B 2.67B 2.80B 2.92B
Net Income 759.90M -1.84B -637.32M -3.63B 4.25B
EPS (Diluted) 27.87 -65.36 -21.82 -121.79 140.83
Gross Profit 1.34B 1.38B 1.43B 1.57B 1.64B
Operating Income 270.50M 269.00M 337.80M 482.62M 500.34M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 10.58B 9.36B 12.30B 13.50B 17.80B
Total Liabilities 3.12B 2.79B 3.56B 3.89B 4.11B
Shareholders' Equity 7.45B 6.57B 8.74B 9.62B 13.69B
Total Debt 1.53B 1.37B 1.41B 1.39B 223.38M
Cash & Equivalents 531.80M 488.10M 403.80M 434.22M 470.78M
Current Assets 2.91B 3.03B 3.05B 3.16B 1.99B
Current Liabilities 517.00M 467.80M 522.80M 568.71M 680.94M

Puntuaciones de Estrategias

This stock passed the criteria for 2 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Deep Value Investing (Seth Klarman)
#605 of 820
33
Value Defensive Investing (Benjamin Graham)
#258 of 708
35

Actividad Reciente

Entró Deep Value Investing (Seth Klarman)
Mar 24, 2026
Entró Defensive Investing (Benjamin Graham)
Mar 24, 2026